32 results were returned
On 20 April 2019, the Standing Committee of the National People's Congress ("NPC") held a second deliberation meeting to discuss the Draft Amendments to Drug Administration Law ("Second Draft DAL Amendments"). A week ...
On 31 March 2020, the “Ministry of Commerce, General Administration of Customs and the National Medical Product Administration (NMPA) issued Notice No. 5 of 2020 – Notice on the Orderly Conducting of Medical Materials ...
Overall, the new DRR and AMMDP provide further clarity to the provisions of the new DAL. The obvious step toward improving the review and approval process, and the reduction in the need for onsite review for many ...
On 27 November 2020, the China National Intellectual Property Administration (“CNIPA”) issued the draft Implementing Regulations of the PRC Patent Law (“Draft Amendments for Implementing Regulations”) for public ...
On 17 October 2020, China's Standing Committee of the National People's Congress ("NPC") passed the amendments for the Patent Law of China ("Patent Law Amendments 2020"), which will come into effect on 1 June 2021.
The restating of the expedited review pathways, and the recently published work procedures, appear to be a step toward improving a process that has seemingly changed numerous times over the years.
As the patent linkage provisions are new for China, the Draft Judicial Interpretations provide some guidance on how the system will be implemented in practice. The Draft Judicial Interpretations are open for public ...
On 1 November 2018, the Standing Committee of the People's Congress in China ("NPC") announced two important draft documents for public consultation until 1 December 2018: (1) Drug Administration Law (Amendment Draft) ...
On 1 August 2019, the National Medical Products Administration ("NMPA") issued a notice to extend the pilot project of medical device registrant system (GUO YAO JIAN XIE ZHU (2019) No.33) ("Notice") to 21 ...
DEFAULT DEFAULT Most Relevant Alphabetical Chronological Go
REFINE RESULTS: